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Purpose: To determine how culture results are associated with clinical presentations and 
outcomes in delayed-onset bleb-associated endophthalmitis (BAE).
Methods: Retrospective consecutive case series of BAE at Bascom Palmer Eye Institute between 
January 1, 1996 and December 31, 2009. All patients had prior glaucoma filtering surgery. 
BAE was defined as intraocular infection with vitreous involvement receiving treatment with 
intravitreal antibiotics. Visual acuity (VA) outcomes and other clinical data were grouped by 
culture result and compared using the 2-sided Student’s t-test.
Main outcome measure: Mean logMAR change at 3 months after treatment (3-month 
logMAR∆).
Results: Eighty-six eyes of 85 patients were identified. Two eyes were primarily eviscerated. 
Fifty-three (63%) eyes were culture-positive with the following organisms: Streptococcus, 21 
(25%); coagulase-negative Staphylococcus, 9 (11%); Enterococcus, 6 (7%); Gram-negative, 
15 (18%); Moraxella, 8 (10%); Pseudomonas, 3 (4%); and Serratia, 3 (4%). Presenting 
logMAR VA: culture-positive worse than culture-negative cases (2.45 vs 2.19, P = 0.05). 
Presenting intraocular pressure (IOP): culture-positive higher than culture-negative cases 
(24 mmHg vs 14 mmHg, P = 0.002). Poor presenting view of the fundus: Streptococcus 
worse than coagulase-negative Staphylococcus cases (90% vs 44%, P = 0.006), Pseudomonas 
and Serratia worse than Moraxella cases (100% vs 50%, P = 0.04). Three month logMAR∆: 
culture-positive worse than culture-negative cases (1.03 vs 0.43, P = 0.02), Streptococcus 
worse than coagulase-negative Staphylococcus cases (1.44 vs 0.31, P = 0.004), Pseudomonas 
and Serratia worse than coagulase-negative Staphylococcus cases (2.41 vs 0.31, P = 0.001), 
Pseudomonas and Serratia worse than Moraxella cases (2.41 vs 0.04, P = 0.001). A culture 
result of Streptococcus or Serratia was present in 6 of 7 eyes that received an additional treat-
ment of enucleation or evisceration (P = 0.01).
Conclusion: Culture-positive cases were associated with worse presenting VA, higher present-
ing IOP, and worse VA outcomes than culture-negative cases. Streptococcus, Pseudomonas, and 
Serratia cases were associated with poor presenting view of the fundus and worse VA outcomes 
than coagulase-negative Staphylococcus and Moraxella cases.
Keywords: endophthalmitis, bleb-associated endophthalmitis, trabeculectomy, culture 
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Introduction
Visual acuity (VA) outcomes after treatment of delayed-onset bleb-associated 
endophthalmitis (BAE) are poor.1–10 Only 22%–67% of eyes with BAE achieve a VA 
outcome of 20/400 or better. The most frequent causative organisms isolated include 
Streptococcus sp. and Gram-negative organisms in 31%–57% and 15%–32% of cases, 





The association between culture results and VA out-
comes has been addressed in small case series.1–6 In one 
study there was no significant difference between VA out-
comes of eyes with Streptococcus sp., non-Streptococcus 
Gram-positive organisms, and Gram-negative organisms.2 
Another study showed no significant difference between 
VA outcomes of eyes with Streptococcus and Staphylo-
coccus sp.3 Others reported VA outcomes for eyes with 
Streptococcus sp. and non-Streptococcus organisms but 
did not perform a comparative analysis.4–6 The inability to 
identify a significant association between VA outcomes and 
culture result may be due to the relatively small number of 
reported BAE cases and the pre-existing ocular disease in 
these patients.
It is also unclear if the clinical presentation of BAE differs 
by culture result. Presently no studies have reported present-
ing clinical information (eg, intraocular pressure, presence of 
hypopyon, view of the fundus) by culture result. The purpose 
of the current study is to determine how culture results are 
associated with clinical presentations and outcomes in BAE by 
performing a comparative analysis within a large case series.
Methods
The study protocol was approved by the Institutional Review 
Board of the University of Miami Miller School of Medi-
cine Subcommittee for the Protection of Human Subjects in 
Research. The medical records and microbiologic records 
of all patients treated for BAE at Bascom Palmer Eye 
Institute (BPEI) between January 1, 1996 and December 
31, 2009 were reviewed. All patients had prior glaucoma 
filtering surgery. BAE was defined as intraocular infection 
with vitreous involvement receiving treatment with intrav-
itreal antibiotics. Patients with tube shunts as the filtering 
mechanism, bleb infection only (no posterior inflammation), 
onset within 1 month of glaucoma surgery, and inadvertent 
filtering blebs after cataract surgery were excluded. Clinical 
history and presentation, treatment, intraocular culture data, 
VA outcomes, and factors affecting VA were recorded. The 
current study included clinical information from the series 
of 71 eyes treated at BPEI between January 1, 1996 and July 
1, 2008, which has been reported previously.1
Snellen VAs were converted to logMAR equivalents for 
statistical analysis; VAs of hand motion, light perception, and 
no light perception were assigned logMAR values of 2.6, 3, 
and 4 respectively. Change in VA was determined by compar-
ing the last recorded VA before the onset of endophthalmitis 
with VA at 3 months. The mean logMAR change at 3 months 
after presentation (3-month logMAR∆) and other clinical 
data were grouped by culture result and compared using the 
2-sided Student’s t-test. A P-value of  #0.05 was considered 
statistically significant.
Results
Eighty-six eyes of 85 patients were identified. Two eyes were 
primarily eviscerated. Intraocular culture results were positive 
in 53 of 84 eyes, 63% Streptococcus sp. and   Gram-negative 
organisms were the most frequent isolates, accounting for 25% 
and 18% of cases respectively. In five eyes, two organisms 
were isolated. All isolated organisms were sensitive to the 
intravitreal antibiotics clinically administered which included 
Vancomycin and Ceftazidime in 77 eyes, 92%, Vancomycin 
and Amikacin in two eyes, Vancomycin and Gentamicin in 
one eye, Vancomycin alone in two eyes, Ceftazidime and Ami-
kacin in one eye, and Cefazolin and Gentamicin in one eye. 
Intravitreal Dexamethasone injections were given to 69 eyes, 
82%. All eyes received topical antibiotics and steroids.
A comparison of culture-positive and culture-negative 
cases showed no significant difference in baseline demo-
graphics (Table 1). A greater number of culture-positive 
cases presented with a poor view of the fundus. The mean 
presenting intraocular pressure (IOP) was higher in culture-
positive cases with no significant difference in final IOP. 
The mean pre-endophthalmitis VA showed no significant 
difference between groups, however mean presenting VA 
and 3-month logMAR∆ were worse in culture-positive cases 
(Figures 1 and 2).
Comparing Streptococcus cases with non-Streptococcus 
Gram-positive and coagulase-negative Staphylococcus cases 
showed no significant difference in baseline demograph-
ics (Table 2). The Streptococcus cases presented with a 
higher mean IOP and greater number of cases with a poor 
view of the fundus. A higher number of coagulase-negative 
Staphylococcus cases received tap and injection as the initial 
treatment. There was no significant difference in mean pre-
endophthalmitis VA or presenting VA, however 3-month 
logMAR∆ was significantly worse in Streptococcus cases 
(Figure 3).
A comparison of Gram-negative cases with coagulase-neg-
ative Staphylococcus cases showed that fewer Gram-negative 
cases achieved VA $ 20/400 at 3 months (Table 3). Pseudomo-
nas and Serratia cases were associated with a poor view of 
the fundus, higher mean presenting IOP, and a worse 3-month 
logMAR∆ compared with coagulase-negative Staphylococcus 
cases. Pseudomonas and Serratia cases were also associated 
with a poor view of the fundus and worse 3-month logMAR∆ 





Table 1 Culture-positive and culture-negative cases
Culture-positive  Culture-negative
53/84 (63%) 31/84 (37%)
Age
  Mean, sD 75 (12) 71 (13)
gender
  Female 26 (50%) 15 (48%)
  Male 26 (50%) 16 (52%)
Diabetes mellitus
  Present 6 (12%) 5 (17%)
  Absent 46 (88%) 25 (83%)
Antimetabolites
  Used 33 (64%) 20 (69%)
  not used 19 (36%) 9 (31%)
Bleb leak
  Present 10 (19%) 11 (35%)
  Absent 43 (81%) 20 (65%)
Mean time of onset of 
endophthalmitis, sD
64 months (46) 49 months (42)
Anterior chamber
hypopyon 36 (68%) 23 (74%)
View to fundus
  hazy 15 (28%) 15 (48%)
  Poor/none 38 (72%) 16 (52%)
intraocular pressure
  Presentation, sD 24 (15) 14 (9)*
Treatment, initial
  Tap and injection 30 (57%) 24 (77%)
  Pars plana vitrectomy 23 (43%) 7 (23%)
Treatment, additional
  Filtering procedure 7 (13%) 6 (19%)
  Pars plana vitrectomy 19 (36%) 5 (16%)*
VA before endophthalmitis n = 50 n = 31
  Mean 20/81 20/95
  range 20/20-LP 20/25-CF
Presenting VA n = 53 n = 31
  Mean 0.7/200 1.6/200*
  range 20/40-nLP 20/50-LP
VA 3 months posttreatment n = 47 n = 19
  Mean 4.1/200 20/209*
  range 20/25-nLP 20/25-LP
  20/400 or better 26 (55%) 14 (74%)
LogMAR∆ 1.03 0.43*
Note: *P # 0.05, culture-positive compared to culture-negative cases.
Abbreviations: CF, counting fingers; LP, light perception; NLP, no light perception; 
SD, standard deviation; VA, visual acuity.
Figure 1 Photograph of right eye of 66-year-old male presenting with BAe from 
Streptococcus sp. Presenting VA: hM, iOP: 28 mmhg. Treatment: tap and injection. 
Final VA: hM, iOP: 12 mmhg. Culture-positive cases were associated with worse 
presenting VA and higher presenting iOP than culture-negative cases.
Abbreviations:  BAE,  bleb-associated  endophthalmitis;  HM,  hand  motion;  IOP, 
intraocular pressure; VA, visual acuity.
Figure  2  Photograph  of  left  eye  of  67-year-old  male  presenting  with  culture-
negative BAe. Presenting VA: 20/200, iOP: 10 mmhg. Treatment: tap and injection. 
Final VA 20/200, iOP 16 mmhg. Culture-negative cases were associated with better 
VA outcomes than culture-positive cases.
Abbreviations: BAE, bleb-associated endophthalmitis; IOP, intraocular pressure; 
VA, visual acuity.
Streptococcus and Serratia cases were associated with 
enucleation or evisceration (Table 4). Six of seven eyes that 
received an additional treatment of enucleation or eviscera-
tion had a culture result of Streptococcus or Serratia sp.
Discussion
The current study reports associations between culture 
results and clinical presentations and outcomes not clearly 
demonstrated in previous BAE series. The inability to detect 
these associations in past studies may have been due to the 
limited power inherent in smaller case series and the man-
ner in which VA outcomes were analyzed. Previous BAE 
studies reported the percentage of eyes $ 20/400 or the loss 
of $5 Snellen lines.1–6 While this information is clinically 
descriptive, it may be limited for comparative purposes by 
the poor baseline VA of many glaucomatous eyes. Mean 
logMAR∆ more precisely measures VA outcomes in low 
vision eyes.
The broad groups of causative organisms used in past 
BAE case series may also have limited the ability to detect 
associations with VA outcomes. A previous BAE case series 
used the classification of non-Streptococcus Gram-positive 
organisms.2 Non-Streptococcus Gram-positive organ-
isms include a wide range of organisms such as Staphy-





Figure  3  Photograph  of  left  eye  of  79-year-old  female  presenting  with  BAe 
from Streptococcus sp. Presenting VA: LP, iOP: 40 mmhg. Treatment: pars plana 
vitrectomy. Final VA: LP, iOP: 0 mmhg. Only 45% of Streptococcus cases had VA 
outcomes $ 20/400.
Abbreviations: BAE, bleb-associated endophthalmitis; IOP, intraocular pressure; 
LP, light perception; VA, visual acuity.






21/84 (25%) 17/84 (20%) 9/84 (11%) 6/84 (7%)
Age
  Mean, sD 72 (14) 77 (8) 77 (9) 76 (9)
gender
  Female 9 (45%) 7 (41%) 3 (33%) 3 (50%)
  Male 11 (55%) 10 (59%) 6 (67%) 3 (50%)
Diabetes mellitus
  Present 2 (10%) 1 (6%) 1 (11%) 0 (0%)
  Absent 18 (90%) 16 (94%) 8 (89%) 6 (100%)
Antimetabolites
  Used 11 (55%) 14 (82%) 9 (100%) 3 (50%)
  not used 9 (45%) 3 (18%) 0 (0%) 3 (50%)
Bleb leak
  Present 4 (19%) 4 (24%) 3 (33%) 1 (17%)
  Absent 17 (81%) 13 (76%) 6 (67%) 4 (67%)
Anterior chamber
hypopyon 11 (52%) 13 (77%) 7 (78%) 4 (67%)
View to fundus
  hazy 2 (10%) 9 (53%) 5 (56%) 2 (33%)
  Poor/none 19 (90%) 8 (47%)* 4 (44%)† 4 (67%)
Mean time of onset of endophthalmitis, sD 71 months (40) 64 months (57) 57 months (58) 77 months (72)
intraocular pressure
  Presentation, sD 29 (16) 18 (15)* 11 (8)† 30 (17)
Treatment, initial
  Tap and injection 9 (43%) 12 (71%) 8 (89%)† 3 (50%)
  Pars plana vitrectomy 12 (57%) 5 (29%) 1 (11%) 3 (50%)
Treatment, additional
  Filtering procedure 2 (10%) 5 (29%) 4 (44%)† 0 (0%)
  Pars plana vitrectomy 10 (48%) 3 (18%)* 1 (11%)† 2 (33%)
VA before endophthalmitis n = 19 n = 17 n = 9 n = 6
  Mean 20/62 20/73 20/54 20/167
  range 20/20-4/200 20/20-LP 20/25-20/200 20/25-LP
Presenting VA n = 21 n = 17 n = 9 n = 6
  Mean 0.5/200 0.8/200 1/200 0.5/200
  range 20/40-LP 20/80-nLP 20/200-LP 20/80-nLP
VA 3 months posttreatment n = 20 n = 14 n = 9 n = 4
  Mean 1.9/200 20/209* 20/110† 3/200
  range 20/30-nLP 20/25-LP 20/25-hM 20/100-LP
  20/400 or better 9 (45%) 11 (79%)* 8 (89%)† 2 (50%)
LogMAR∆ 1.44 0.46* 0.31† 0.89
Notes: *P # 0.05, Streptococcus compared to non-Streptococcus Gram-positive cases; †P # 0.05, Streptococcus compared to coagulase-negative Staphylococcus cases.
Abbreviations: HM, hand motion; LP, light perception; NLP, no light perception; SD, standard deviation; VA, visual acuity.
  Staphylococcus cases that have varying VA outcomes. The 
current study narrowed the analysis to individual causative 
organisms, strengthening associations with VA outcomes.
An analysis of Gram-negative cases by individual organ-
ism showed that Pseudomonas and Serratia cases had worse 
mean VA outcomes than Moraxella cases. The relatively 
good VA outcomes of Moraxella cases, 71% $ 20/400, 
confirms the previous report by Berrocal et al of favorable 
outcomes with Moraxella cases.11
The current study also provides insight into the clinical 
presentation of causative organisms in BAE.   Streptococcus, 





Table 3 gram-negative cases
Gram-negative Moraxella Pseudomonas Serratia
15/84 (18%) 8/84 (10%) 3/84 (4%) 3/84 (4%)
Age
  Mean, sD 78 (14) 72 (11) 82 (18) 89 (12)
gender
  Female 10 (67%) 4 (50%) 3 (100%) 2 (67%)
  Male 5 (33%) 4 (50%) 0 (0%) 1 (33%)
Diabetes mellitus
  Present 3 (20%) 2 (25%) 1 (33%) 0 (0%)
  Absent 12 (80%) 6 (75%) 2 (67%) 3 (100%)
Antimetabolites
  Used 8 (53%) 5 (63%) 1 (33%) 2 (67%)
  not used 7 (47%) 3 (37%) 2 (67%) 1 (33%)
Bleb leak
  Present 2 (13%) 2 (75%) 0 (0%) 0 (0%)
  Absent 13 (87%) 6 (75%) 3 (100%) 3 (100%)
Anterior chamber
hypopyon 12 (80%) 6 (75%) 2 (67%) 3 (100%)
View to fundus
  hazy 4 (27%) 4 (50%) 0 (0%) 0 (0%)
  Poor/none 11 (73%) 4 (50%)† 3 (100%) 3 (100%)‡
Mean time of onset of endophthalmitis, sD 51 months (36) 56 months (32) 57 months (77) 34 months (38)
intraocular pressure
  Presentation, sD 22 (12)* 23 (15) 26 (12) 18 (4)‡
Treatment, initial
  Tap and injection 9 (60%) 5 (63%) 1 (33%) 2 (67%)
  Pars plana vitrectomy 6 (40%) 3 (37%) 2 (67%) 1 (33%)
Treatment, additional
  Filtering procedure 0 (0%) 0 (0%) 0 (0%) 0 (0%)
  Pars plana vitrectomy 6 (40%)* 4 (50%)† 0 (0%) 1 (33%)
VA before endophthalmitis n = 14 n = 7 n = 3 n = 3
  Mean 20/131 20/194 20/141 20/74
  range 20/25-hM 20/25-hM 20/40-4/200 20/50-20/100
Presenting VA n = 15 n = 8 n = 3 n = 3
  Mean 0.9/200 1.4/200 1.6/200 LP
  range 20/80-LP 20/80-LP 20/100-LP hM-LP
VA 3 months posttreatment n = 13 n = 7 n = 2 n = 3
  Mean 2.5/200* 20/264† LP LP‡
  range 20/40-nLP 20/40-hM LP-LP LP-nLP
  20/400 or better 6 (46%)* 5 (71%)† 0 (0%) 0 (0%)‡
LogMAR∆ 1.08 0.04† 1.88 2.77‡
Note: *P # 0.05, gram-negative compared to coagulase-negative Staphylococcus cases.  †P # 0.05, Pseudomonas and Serratia compared to Moraxella cases.  ‡P # 0.05, 
Pseudomonas and Serratia compared to coagulase-negative Staphylococcus cases.
Abbreviations: HM, hand motion; LP, light perception; NLP, no light perception; SD, standard deviation; VA, visual acuity.
Figure 4 Photograph of left eye of 72-year-old female with BAe from Moraxella sp. 
Presenting VA: 1/200, iOP: 35 mmhg. Treatment: tap and injection. Final VA: 20/25, 
iOP: 11 mmhg. Moraxella cases were associated with a better presenting view of the 
fundus and better VA outcomes than Pseudomonas and Serratia cases.
Abbreviations: BAE, bleb-associated endophthalmitis; IOP, intraocular pressure; 
VA, visual acuity.
a higher mean IOP and worse view of the fundus than 
  coagulase-negative Staphylococcus cases. Similarly culture 
positive cases were associated with a worse presenting VA and 
higher presenting IOP than culture negative cases. The clini-
cian can consider the increased likelihood of a more virulent 
organism and worse visual prognosis when the patient presents 
with poor VA, high IOP, and poor view of the fundus.
The VA outcome analysis provided in this study confirms 
what clinicians have suspected for decades. Worse VA out-
comes in BAE are associated with the most frequent isolates, 
Streptococcus sp. and Gram-negative organisms such as Clinical Ophthalmology
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Pseudomonas and Serratia sp. When discussing prognosis, 
clinicians may consider that eyes with Streptococcus sp. and 
Gram-negative organisms had VA outcomes $ 20/400 in 
only 45% and 46% of cases respectively while eyes with 
coagulase-negative Staphylococcus sp. Achieved $ 20/400 in 
89% of cases.
Interestingly coagulase-negative Staphylococcus cases 
achieved better VA outcomes despite less aggressive treat-
ment. Only 11% of the coagulase-negative   Staphylococcus 
cases received pars plana vitrectomy compared with 57% 
of the Streptococcus cases. The higher mean IOP and 
worse view of the fundus in the Streptococcus cases likely 
compelled the treating clinician to more frequently favor 
pars plana vitrectomy. The role pars plana vitrectomy plays 
in BAE can only be determined by a sufficiently powered 
prospective randomized control trial. Unfortunately this 
may not be feasible due to the limited number of BAE 
cases.
The current study was not designed to determine the best 
management for BAE, but it does provide insight into the 
key role causative organisms play in the clinical presenta-
tion and prognosis of BAE. Culture-positive cases were 
associated with worse presenting VA, higher presenting 
IOP, and worse VA outcomes than culture-negative cases. 
Streptococcus, Pseudomonas, and Serratia cases were   
associated with poor presenting view of the fundus and 
worse VA outcomes than coagulase-negative Staphylococcus 
and Moraxella cases.
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Table 4 enucleation or evisceration in nine eyes (10%)
Case # Culture result Initial treatment Additional treatment
5 Serratia and Streptococcus T&i enucleation
17 Serratia T&i enucleation
33 Serratia PPV evisceration
26 Streptococcus T&i evisceration
37 Streptococcus PPV enucleation
43 Streptococcus PPV enucleation
46 no growth PPV evisceration
25 not done evisceration
70 not done evisceration  
Note: P = 0.01, enucleation or evisceration for Streptococcus or Serratia compared with other culture results.
Abbreviations: PPV, Pars planavitrectomy; T&I, tap and injection.